Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

Post time 7 day(s) ago

journal：Neurology

Authors：Sahla El Mahdaoui; Luigi Pontieri; Jeppe Romme Christensen; Hiba Alabdalridha; Manuel Demirovic; Luke Karl Harper; Zsolt Illes; Henrik Boye Jensen; Christina Dahl Lindengren; Sepehr Mamoei; Camilla Maersk-Moller; Lucas Rundblad; Jakob Schfer; Tobias Sejbaek; Morten Stilund; Peter Vestergaard Rasmussen; Arkadiusz Weglewski; Finn Sellebjerg; Melinda Magyari;

Published date：2026-10-27

DOI：10.1212/wnl.0000000000218545

PDF link：https://www.neurology.org/doi/pd ... NL.0000000000218545

Article link：https://doi.org/10.1212/wnl.0000000000218545

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 7 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Ovid] Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Ovid] Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Ovid] Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis